Pharmamarketeer

Lilly, Aduro Biotech enter research collaboration to develop novel immunotherapies

Eli Lilly and Company and Aduro Biotech, Inc. announced a research collaboration and exclusive license agreement for Aduro’s cGAS─STING Pathway Inhibitor program for the research and development of novel

Medhc-fases-banner
Advertentie(s)